Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

PMID:
31097634
2.

Reducing mortality in newly diagnosed standard-risk acute promyelocytic leukemia in elderly patients treated with arsenic trioxide requires major reduction of chemotherapy: a report by the French Belgian Swiss APL group (APL 2006 trial).

Rahmé R, Ades L, Thomas X, Guerci-Bresler A, Pigneux A, Vey N, Raffoux E, Castaigne S, Spertini O, Wittnebel S, Marolleau JP, Damaj G, Bordessoule D, Lejeune J, Chevret S, Fenaux P.

Haematologica. 2018 Nov;103(11):e519-e521. doi: 10.3324/haematol.2018.193151. Epub 2018 May 24. No abstract available.

PMID:
29794147
3.

Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.

Maertens J, Graux C, Breems D, Havelange V, Wittnebel S, Strens D, Hoefkens C.

Acta Clin Belg. 2017 Dec;72(6):429-433. doi: 10.1080/17843286.2017.1314091. Epub 2017 Apr 13.

PMID:
28406385
4.

Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial.

Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F.

Haematologica. 2017 Feb;102(2):e47-e51. doi: 10.3324/haematol.2016.153130. Epub 2016 Oct 27. No abstract available.

PMID:
27789677
5.

Risk-adapted transplant strategies for high-risk Hodgkin lymphoma: are we there?

Lewalle P, Wittnebel S.

Curr Opin Oncol. 2016 Sep;28(5):390-7. doi: 10.1097/CCO.0000000000000312. Review.

PMID:
27467971
6.

Photo quiz. Dyspnea and fever in an allogeneic stem cell recipient.

Angoulvant A, Stern JB, Wittnebel S, Bourhis JH, Gachot B, Vittecoq D, Wyplosz B.

Clin Infect Dis. 2015 Jan 1;60(1):100, 157-8. doi: 10.1093/cid/ciu839. No abstract available.

PMID:
25504499
7.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

PMID:
24894084
8.

Skin ulcers related to chronic graft-versus-host disease: clinical findings and associated morbidity.

Jachiet M, de Masson A, Peffault de Latour R, Rybojad M, Robin M, Bourhis JH, Xhaard A, Dhedin N, Sicre de Fontbrune F, Suarez F, Barete S, Parquet N, Nguyen S, Ades L, Rubio MT, Wittnebel S, Bagot M, Socié G, Bouaziz JD.

Br J Dermatol. 2014 Jul;171(1):63-8. doi: 10.1111/bjd.12828. Epub 2014 Jun 24.

PMID:
24404963
9.

Limited efficacy and tolerance of imatinib mesylate in steroid-refractory sclerodermatous chronic GVHD.

de Masson A, Bouaziz JD, Peffault de Latour R, Wittnebel S, Ribaud P, Rubio MT, Micol JB, Suarez F, Nguyen S, Dalle JH, Yakouben K, Robin M, Xhaard A, Adès L, Bourhis JH, Rybojad M, Bagot M, Socié G.

Blood. 2012 Dec 13;120(25):5089-90. doi: 10.1182/blood-2012-09-453928. No abstract available.

PMID:
23243159
10.

Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.

Crickx E, Wittnebel S, Pasquier F, Danu A, Bourhis JH, Ribrag V, Boué F, Miceli C, Mariette X, Moreau P, Botton Sd, Ghez D.

Eur J Cancer. 2013 Jan;49(2):411-5. doi: 10.1016/j.ejca.2012.08.009. Epub 2012 Sep 12.

PMID:
22980726
11.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT).

Biol Blood Marrow Transplant. 2012 May;18(5):788-93. doi: 10.1016/j.bbmt.2011.10.010. Epub 2011 Oct 17.

PMID:
22005647
12.

The t(1;9)(p34;q34) fusing ABL1 with SFPQ, a pre-mRNA processing gene, is recurrent in acute lymphoblastic leukemias.

Duhoux FP, Auger N, De Wilde S, Wittnebel S, Ameye G, Bahloula K, Van den Berg C, Libouton JM, Saussoy P, Grand FH, Demoulin JB, Poirel HA.

Leuk Res. 2011 Jul;35(7):e114-7. doi: 10.1016/j.leukres.2011.02.011. Epub 2011 Mar 9. No abstract available.

PMID:
21388681
13.

Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.

Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, Escudier B, Azzarone B, Caignard A.

Oncogene. 2011 Jun 9;30(23):2622-32. doi: 10.1038/onc.2010.638. Epub 2011 Jan 24.

PMID:
21258414
14.

Early evaluation of natural killer activity in post-transplant acute myeloid leukemia patients.

Pittari G, Fregni G, Roguet L, Garcia A, Vataire AL, Wittnebel S, Amsellem S, Chouaib S, Bourhis JH, Caignard A.

Bone Marrow Transplant. 2010 May;45(5):862-71. doi: 10.1038/bmt.2009.265. Epub 2009 Oct 5.

PMID:
19802033
15.

[Prolonged acute pancreatitis after bone marrow transplantation].

De Singly B, Simon M, Bennani J, Wittnebel S, Zagadanski AM, Pacault V, Gornet JM, Allez M, Lémann M.

Gastroenterol Clin Biol. 2008 Apr;32(4):413-6. doi: 10.1016/j.gcb.2007.10.007. Epub 2008 Apr 2. French.

PMID:
18378104
16.

Membrane-bound interleukin (IL)-15 on renal tumor cells rescues natural killer cells from IL-2 starvation-induced apoptosis.

Wittnebel S, Da Rocha S, Giron-Michel J, Jalil A, Opolon P, Escudier B, Validire P, Khawam K, Chouaib S, Azzarone B, Caignard A.

Cancer Res. 2007 Jun 15;67(12):5594-9.

PMID:
17575122
17.

Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue.

Wittnebel S, Bourhis JH, Caignard A.

Expert Rev Clin Immunol. 2006 Jul;2(4):627-37. doi: 10.1586/1744666X.2.4.627.

PMID:
20477618
18.

The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.

Cebo C, Da Rocha S, Wittnebel S, Turhan AG, Abdelali J, Caillat-Zucman S, Bourhis JH, Chouaib S, Caignard A.

J Immunol. 2006 Jan 15;176(2):864-72.

PMID:
16393970
19.

The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax.

Wittnebel S, Jalil A, Thiery J, DaRocha S, Viey E, Escudier B, Chouaib S, Caignard A.

Eur Cytokine Netw. 2005 Jun;16(2):123-7.

PMID:
15941683
20.

Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.

Mackensen A, Wittnebel S, Veelken H, Noppen C, Spagnoli GC, Lindermann A.

Eur Cytokine Netw. 1999 Sep;10(3):329-36.

PMID:
10477389
21.

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts.

Mackensen A, Veelken H, Lahn M, Wittnebel S, Becker D, Köhler G, Kulmburg P, Brennscheidt U, Rosenthal F, Franke B, Mertelsmann R, Lindemann A.

J Mol Med (Berl). 1997 Apr;75(4):290-6.

PMID:
9151215

Supplemental Content

Loading ...
Support Center